28 Jan. 2022 05:00 o’clock
Clinical trials of a nasal corona vaccine have started in Moscow. The tests, which are expected to last 180 days, will involve 400 volunteers.
Moscow Deputy Mayor Anastasiya Rakova said on Wednesday that 400 people will take part in the first two phases of the study. The new administration form is the Sputnik V vaccine in the same dosage, but in the form of a nasal spray.
The researchers want to determine within 180 days whether the study participants developed antibodies against the corona virus.
The study is open to people over 18 years of age without chronic diseases, who have not been vaccinated against SARS-CoV-2 in the past six months and who have not had COVID-19, said Darya Kurguzova, a clinical trials specialist at Sechenov University in Moscow. Neither the researchers nor the subjects know who is actually being immunized and who is just receiving placebos.
The nasal vaccine was developed at the Gamaleja Center, where the Sputnik V vaccine was also developed. The spray creates local immunity in the nasopharynx and creates a protective barrier against the virus. Center director Alexander Ginzburg explained last week that the intranasal vaccine could curb the spread of the omicron variant: “If we had it now, we would spray the intranasal vaccine into everyone’s nose so that they don’t get infected.”
Russia is currently struggling with a sharp increase in the number of cases. The main reason for this is the Omikron variant, which is rapidly gaining ground. According to the crisis team, a new high of 88,816 cases was recorded in the past 24 hours. Most new infections were in Moscow and Saint Petersburg. 47 percent of the population are currently fully vaccinated.
more on the subject – Italian study: Sputnik V against Omicron more than twice as effective as Pfizer